AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like 4 Large Cap Pharmas That Could Post Huge Earnings October 19, 2017 Adaptimmune's CMO Moves Forward with SPEAR T Cell Therapies January 9, 2018 Bay Area's Eureka Therapeutics Banks $60M January 21, 2018
